Search Orphan Drug Designations and Approvals
-
Generic Name: | triheptanoin |
---|---|
Trade Name: | Dojolvi |
Date Designated: | 04/15/2015 |
Orphan Designation: | Treatment of fatty acid oxidation disorders |
Orphan Designation Status: | Designated/Approved |
Marketing Approval Date: | 06/30/2020 |
Approved Labeled Indication: | DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). |
Exclusivity End Date: | 06/30/2027 |
Exclusivity Protected Indication* : | Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). |
Sponsor: |
Ultragenyx Pharmaceutical, Inc. 60 Leveroni Court Novato, California 94949 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-